Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus

Georgios Zacharakis; Jaman Alzahrani

doi:10.5812/hepatmon.12531

Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus

Georgios Zacharakis, Jaman Alzahrani

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.

Original language	English
Article number	e12531
Journal	Hepatitis Monthly
Volume	18
Issue number	1
DOIs	https://doi.org/10.5812/hepatmon.12531
State	Published - 20 Jan 2018

Keywords

Coinfection
HBV Reactivation
HCV Direct Acting Antivirals
Hepatitis B
Hepatitis C
Nucleos(t)ide Analogues

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5812/hepatmon.12531

Cite this

@article{3496530fc3d84165aca99cdbe7f15478,

title = "Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus",

abstract = "Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.",

keywords = "Coinfection, HBV Reactivation, HCV Direct Acting Antivirals, Hepatitis B, Hepatitis C, Nucleos(t)ide Analogues",

author = "Georgios Zacharakis and Jaman Alzahrani",

note = "Publisher Copyright: {\textcopyright} 2018, Hepatitis Monthly.",

year = "2018",

month = jan,

day = "20",

doi = "10.5812/hepatmon.12531",

language = "English",

volume = "18",

journal = "Hepatitis Monthly",

issn = "1735-143X",

publisher = "Brieflands",

number = "1",

}

TY - JOUR

T1 - Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus

AU - Zacharakis, Georgios

AU - Alzahrani, Jaman

PY - 2018/1/20

Y1 - 2018/1/20

N2 - Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.

AB - Introduction: The recent use of new direct-acting drugs (DAAs) in the treatment of chronic hepatitis C needs to be evaluated in HBV/HCV coinfected patients. Case Presentation: Here, we report the case of a 47-year-old female patient with HBV/HCV coinfection who experienced HBV reactivation during treatment with daclatasvir (DCV) and sofosbuvir (SOF). In addition to the DAAs, Entecavir (ETV) was added to the combined regimen with improvement in ALT levels. Conclusions: Both HBV and HCV treatment could be implemented effectively in case of reactivation of HBV during anti-HCV treatment with DAAs. Close monitoring of HBV DNA and ALT levels are highly recommended during DAAs drug therapy for HCV in patients with HBV/HCV dual infection.

KW - Coinfection

KW - HBV Reactivation

KW - HCV Direct Acting Antivirals

KW - Hepatitis B

KW - Hepatitis C

KW - Nucleos(t)ide Analogues

UR - http://www.scopus.com/inward/record.url?scp=85042665427&partnerID=8YFLogxK

U2 - 10.5812/hepatmon.12531

DO - 10.5812/hepatmon.12531

M3 - Article

AN - SCOPUS:85042665427

SN - 1735-143X

VL - 18

JO - Hepatitis Monthly

JF - Hepatitis Monthly

IS - 1

M1 - e12531

ER -

Reactivation of hepatitis b virus during treatment of hepatitis C genotype 3 with daclatasvir and sofosbuvir in a patient with dual infection of hepatitis B and hepatitis C virus

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this